ENYO Pharma Announces Positive Vonafexor (EYP001) Results for the LIVIFY Phase 2a Study in F2-F3 NASH Patients over 12 weeks

首圖 LYON, France — (BUSINESS WIRE) — ENYO Pharma (ENYO), a private clinical stage biotechnology company developing innovative drug candidates, today announced that Vonafexor met the primary an…


發佈留言